AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has received approval from the US Food and Drug Administration (FDA) for an expanded indication of ...

seeking approval for expanded use of Enhertu (trastuzumab deruxtecan) for HER2-low metastatic breast cancer in the United States. The approval of the added indication has triggered a $175 million ...

In the DESTINY-Breast03 trial, Enhertu (trastuzumab deruxtecan) reduced the risk of disease progression or death compared to Kadcyla (trastuzumab emtansine) by 72% in patients with HER2-positive ...

The results – simultaneously published in the journal Nature Medicine – also reveal an objective response rate (ORR) of 62.7% with Enhertu (trastuzumab deruxtecan), of which 9.5% were complete ...

Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has shown clinically meaningful 'improvement' in the DESTINY-Gastric04 Phase III trial, regarding the primary endpoint of ...

Enhertu’s parts and active ingredients are: An antibody (with the ingredient fam-trastuzumab): This part ... Chemotherapy (with the ingredient deruxtecan-nxki): This part of the drug hinders ...

AstraZeneca (AZN) and Daiichi Sankyo’s (DSNKY) trastuzumab deruxtecan has been recommended ... was 13.2 months in patients randomized to Enhertu compared to 8.1 months in those randomized ...

Novel HER2 therapies show strong intracranial efficacy, enabling systemic treatment over local therapy for small, ...

Experts discuss treatment options for HER2-positive metastatic breast cancer following progression on trastuzumab deruxtecan (T-DXd), weighing real-world data on tucatinib-capecitabine-trastuzumab ...

Dr. Sara M. Tolaney discussed HER2-positive breast cancer, highlighting key trials, evolving treatment strategies, and the ...

The safety profile of the novel antibody-drug conjugate was "manageable" and comparable to that of a similar drug, trastuzumab deruxtecan, researchers said. If approved, trastuzumab rezetecan ...